XWELL INC (XWEL)
NASDAQHealth CarePersonal Products & ServicesSnapshot 2026-10-29
NASDAQHealth CarePersonal Products & ServicesSnapshot 2026-10-29
Research Workspace
Put XWEL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Operating income improves toward break-even: Comparison needs review.
View ThesisRevenue is contracting — down about 8% over the past year.
View GrowthManagement screens weak on capital allocation.
View ManagementThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 70% in its worst 12-month stretch.
View RiskXWEL’s thesis rests on improving operating income, though its comparison needs review. No earnings release is recorded, so revenue growth and the latest result are unknown. XWEL has no valuation multiple or peer comparison in the desk. The desk has no priced-in view to show what expectations assume. The next-quarter miss probability is 40%. A Nasdaq notice over minimum bid-price rules raises delisting risk. Operating-income progress is under pressure, but the comparison is unverified. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-30. XWEL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare XWEL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| XWEL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put XWEL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Nasdaq bid-price non-compliance raises delisting risk and signals material share-price weakness.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Advances: Divest XpresSpa and XpresTest businesses for $13 million
The announced $13 million divestiture directly advances the planned sale of XpresSpa and XpresTest.
